Adagio Medical Holdings, Inc. (ADGM) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-27

Key Insights

Adagio Medical announced positive pivotal trial results for its vCLAS® Ventricular Ablation System, a potentially significant milestone that could support regulatory approval and future commercialization of this cardiac ablation device.
The company is an emerging growth company trading on Nasdaq under ticker ADGM, indicating it is a smaller public company in a growth phase with regulatory pathways ahead.
The filing was signed by CFO and Chief Business Officer Deborah Kaster on April 27, 2026, suggesting the company actively manages investor communications and corporate governance.

Want the newest filings?

This analysis covers the filing from 2026-04-27. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-08

Adagio Medical received IDE approval from the FDA to investigate its next-generation vCLAS™ Ventricular Ablation System, indicating progress in the company's product development pipeline.
The filing does not contain any financial information or updates, suggesting this is a regulatory/operational update rather than a performance-related filing.
As an emerging growth company, Adagio Medical may have flexibility in reporting requirements and adoption of new accounting standards, which could impact future financial disclosures.

Filed: 2026-03-27

Adagio Medical Holdings, Inc. announced its Q4 and fiscal year 2025 financial results, providing investors with an update on the company's performance and operations.
The company did not report any material agreements, leadership changes, or other significant events that could impact its business operations or financial condition.
As an emerging growth company, Adagio has elected not to use the extended transition period for complying with new or revised financial accounting standards, which could indicate a focus on transparency and adherence to reporting standards.

Other reports for Adagio Medical Holdings, Inc.

Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.